Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ABO-101
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arbor Biotechnologies Presents ABO-101 Data at ASGCT Annual Meeting
Details : ABO-101, a novel gene editing therapeutic, is currently being evaluated in phase 1 clinical trials. It is designed to treat patients suffering from primary hyperoxaluria type 1.
Brand Name : ABO-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 09, 2024
Lead Product(s) : ABO-101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ALLO-329
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Allogene Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Allogene and Arbor Announce Agreement for Gene Editing in CAR T Platform
Details : Under the agreement, Allogene will use Arbor’s proprietary CRISPR gene-editing technology in its next generation AlloCAR T platform, ALLO-329, for the treatment of autoimmune disease (AID).
Brand Name : ALLO-329
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2024
Lead Product(s) : ALLO-329
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Allogene Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : 4D Molecular Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
4DMT And Arbor Partner To Co-Develop Next-Gen Genetic Medicines For CNS Diseases
Details : 4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system diseases, including amyotrophic lateral sclerosis.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : 4D Molecular Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Expanded Collaboration
Details : Under the terms of the agreement, Vertex Pharmaceuticals incorporated will receive rights to Arbor’s novel precision editing technology for up to three diseases.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : LNP-based Gene Therapy
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Acuitas
Deal Size : Undisclosed
Deal Type : Agreement
Details : As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver disease...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 25, 2022
Lead Product(s) : LNP-based Gene Therapy
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Acuitas
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Gavocabtagene autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : TCR2 Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration leverages Arbor’s proprietary CRISPR gene-editing technology and TCR 2’s’ TRuC platform, which has demonstrated clinical activity in multiple treatment-refractory mesothelin-expressing solid tumor indications with its lead autolog...
Brand Name : Gavo-cel
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : Gavocabtagene autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : TCR2 Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nuclease Therapies
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery
Sponsor : Temasek Life Sciences Laboratory
Deal Size : $215.0 million
Deal Type : Series B Financing
Details : Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of ge...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 09, 2021
Lead Product(s) : Nuclease Therapies
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Sponsor : Temasek Life Sciences Laboratory
Deal Size : $215.0 million
Deal Type : Series B Financing
Lead Product(s) : Ex-vivo Engineered Cell Therapies
Therapeutic Area : Endocrinology
Study Phase : Discovery Platform
Sponsor : Vertex Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Collaboration
Details : Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the trea...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : Ex-vivo Engineered Cell Therapies
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Sponsor : Vertex Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Collaboration
Lead Product(s) : Engineered hematopoietic stem cell
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Vor Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The agreement aims to utilize Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia.
Brand Name : VOR33
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 29, 2020
Lead Product(s) : Engineered hematopoietic stem cell
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Vor Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?